CAMBRIDGE, Mass., Nov. 29, 2022 — Rgenta Therapeutics Inc. today announced the completion of a USD 52 million Series A round-headed by AZ-CICC Healthcare Investment Fund, with participation from all current and new investors, including Korean Investment Partners and Delos Capital. Rgenta Therapeutics focuses on developing RNA-targeting therapeutics for hitherto untreatable disease targets.
Rgenta has an integrative discovery platform that analyzes massive amounts of human genomics data to identify regulatory sites in RNAs amenable to selective modulation by small molecules and then rapidly screens for drug-like small molecules to target RNAs and thus regulate protein production or alter protein functions. The USD 52 million fresh funding will accelerate the development of the lead projects, improve target discovery, expand platform capabilities, and advance a pipeline of promising RNA-targeting medicines across various illness indications.
“We are very delighted to welcome our new investors, and we thank our previous investors for their ongoing support, ” said Simon Xi, co-founder, and CEO of Rgenta. With this funding, we are now well positioned to construct an attractive pipeline, bring our current initiatives into the clinic, and develop breakthrough RNA-targeted treatments to assist patients.”
A robust syndicate of the lead investors, including Boehringer Ingelheim Venture Fund, Lilly Asia Venture, Matrix Partners China, , and Vivo Capital, seeded Rgenta. Including the AZ-CICC Healthcare Investment Fund and the additional Series A investors broadens Rgenta’s strong investor base and allows the company’s cancer and neurology initiatives to advance.
“We’ve been interested in the RNA-targeting field for a long time and have been very impressed with the unique capabilities that Rgenta has built over the last few years to discover and develop the RNA-targeting small molecules, as well as the progress they’ve made on the lead programmes,” said Chen Bing, Managing Director of AZ-CICC Healthcare Investment Fund, Vice President of AstraZeneca China, and Head of Business Development.
More about the startup:
Rgenta Therapeutics is building an oral, small-molecule RNA-targeting pharmaceutical pipeline, with an initial emphasis on cancer and neurological illnesses. Our patented technology mines vast genomics data to find targetable RNA processing events and build small-molecule glues to influence spliceosome, regulatory protein, and RNA interactions. Our pioneering programs and distinct approach are unlocking the therapeutic potential of previously intractable targets in human diseases.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
